NRx Pharmaceuticals (NASDAQ:NRXP) Rating Lowered to Strong Sell at Zacks Research

NRx Pharmaceuticals (NASDAQ:NRXP) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Wednesday,Zacks.com reports.

A number of other research analysts have also weighed in on NRXP. Weiss Ratings reissued a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 5th. HC Wainwright restated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Tuesday. UBS Group restated a “buy” rating on shares of NRx Pharmaceuticals in a report on Wednesday. D. Boral Capital reiterated a “buy” rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Finally, BTIG Research reissued a “buy” rating and set a $10.00 price target on shares of NRx Pharmaceuticals in a report on Tuesday, August 18th. Five analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, NRx Pharmaceuticals has an average rating of “Hold” and a consensus target price of $34.50.

NRx Pharmaceuticals Price Performance

Shares of NRXP stock opened at $3.62 on Wednesday. The company has a fifty day moving average price of $3.72 and a two-hundred day moving average price of $3.05. NRx Pharmaceuticals has a one year low of $1.62 and a one year high of $5.05. The stock has a market cap of $156.75 million, a P/E ratio of -6.58 and a beta of 2.18.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its earnings results on Monday, August 17th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.33). The firm had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.33 million. As a group, equities research analysts anticipate that NRx Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On NRx Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC raised its holdings in shares of NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after buying an additional 37,598 shares in the last quarter. Vanguard Group Inc. grew its position in NRx Pharmaceuticals by 18.3% in the third quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after acquiring an additional 82,781 shares during the last quarter. Two Sigma Investments LP raised its stake in NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after acquiring an additional 20,880 shares in the last quarter. Global Retirement Partners LLC bought a new position in shares of NRx Pharmaceuticals in the fourth quarter worth about $107,000. Finally, Bleakley Financial Group LLC bought a new position in shares of NRx Pharmaceuticals in the fourth quarter worth about $318,000. Institutional investors own 4.27% of the company’s stock.

More NRx Pharmaceuticals News

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating on NRx Pharmaceuticals, signaling continued confidence in the company’s longer-term prospects despite weaker near-term estimates. HC Wainwright Reiterates Buy Rating for NRx Pharmaceuticals
• Neutral Sentiment: HC Wainwright still forecasts a potential transition to profitability, with estimated EPS of $0.15 in fiscal 2028, $0.71 in 2029 and $1.14 in 2030. However, those projections remain highly dependent on successful execution and future revenue growth.
• Negative Sentiment: The analyst cut projected EPS for the third and fourth quarters of 2026 to losses of $0.43 and $0.50, respectively, from previous estimates of losses of $0.06 and $0.07. Forecasts for the first three quarters of 2027 were also reduced to losses of $0.30, $0.15 and $0.05 per share.
• Negative Sentiment: Full-year earnings estimates were sharply lowered: 2027 moved to a $0.50-per-share loss from a $0.67 profit, while estimates for 2028, 2029 and 2030 fell to $0.15, $0.71 and $1.14 from $2.49, $4.51 and $5.76, respectively. These revisions imply slower commercialization or weaker financial performance than previously expected.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.